Gilead HIV Drug Health Risks Were Known Before First TDF-Based Antiretrovirals Hit The Market: Lawsuit
Gilead knew its HIV drugs carried severe health risks before the first ones were placed on the market, the lawsuit claims.
Gilead knew its HIV drugs carried severe health risks before the first ones were placed on the market, the lawsuit claims.
One drug manufacturer has agreed to pay $10 million to resolve its part in allegations that Gilead and other drug makers conspired to keep HIV medication prices artificially high.
A Gilead TDF lawsuit involving about 80 plaintiffs alleges the drug maker exposed patients unnecessarily to toxic effects of its HIV drugs when it had a safer formulation available.
A group of plaintiffs have filed a joint lawsuit against Gilead, claiming it purposefully misled doctors and consumers about the safety of its HIV drugs in order to maximize profits…
A U.S. District Judge has cleared the way for an HIV drug lawsuit to proceed against Gilead, saying the company's actions in how it marketed and sold drugs like Truvada…
Gilead faces an increasing number of lawsuits claiming it sold inferior HIV drugs to maximize profits, while sitting on safer formulas which minimized the risks of kidney and liver injuries.
A group of more than 40 plaintiffs say Gilead unnecessarily marketed toxic HIV drugs which caused kidney and bone injuries while sitting on a safer alternative in order to maximize…
A lawsuit by nearly 30 plaintiffs accuses Gilead of delaying the sale of safer HIV drugs to maximize profits at the expense of patient safety.
A new lawsuit claims Gilead failed to provide proper warnings about the risks of kidney and bone damage from HIV drugs like Truvada, Viread and Atripla.
A new analysis shows Gilead is rapidly convincing Truvada users to switch over to Descovy before the drug goes generic, amid claims it kept the safer drug shelved for years…